Bluebird Bio

Bluebird Bio

A company developing gene therapies for the treatment of genetic diseases and cancer.

Bluebird Bio, formerly Genetix Pharmaceuticals, is a biotechnology company developing multiple therapies for the treatment of genetic diseases and cancer that is headquartered in Cambridge, Massachusetts and was founded in 1993 by Philippe Leboulch. The company is developing gene addition therapies, gene editing therapies, and cancer immunotherapies for treating a variety of health conditions.

Funding
Series A

On June 17, 2004 Bluebird Bio completed their series A funding round with $8.5 million in funding from Nazem and Company and ABN AMRO Fund.

Venture round I

On October 7, 2004 Bluebird Bio completed a venture funding round with $12 million in funding from Techno Venture Management (lead investor), Easton Capital, and ABN AMRO Fund.

Series B

On March 12, 2010 Bluebird Bio completed their series B funding round with $35 million in funding from Third Rock Ventures (lead investor), Sanofi-Genzyme BioVentures (lead investor), TVM Capital, Forbion Capital Partners, and Easton Capital.

Grant

In 2011 Bluebird Bio received a grant worth $9.3 million from The California Institute of Regenerative Medicine (CIRM) to fund their Phase I/II study of LentiGlobin for the treatment of inherited betea-thalas-semia.

Venture round II

On April 20, 2011 Bluebird Bio completed their second venture funding round with $30 million in funding from ARCH Venture Partners (lead investor), Third Rock Ventures, Forbion Capital Partners, TVM Capital, and Easton Capital.

Series D

On July 25, 2012 Bluebird Bio completed their series D funding round with $60 million in funding from Third Rock Ventures, TVM Capital, Ramius Capital, RA Capital Management, Forbion Capital Partners, Deerfield Partners, and ARCH Venture Partners.

Post-IPO equity

On December 7, 2016 Bluebird Bio raised $250 million in post-IPO equity.

Timeline

July 25, 2012
Bluebird Bio raises a $60,000,000 series D round from ARCH Venture Partners, Forbion Capital Partners and Third Rock Ventures.
March 12, 2010
Bluebird Bio raises a $35,000,000 series B round from Forbion Capital Partners and Third Rock Ventures.
1993
Bluebird Bio was founded by Philippe Leboulch.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
bluebird bio funding round, April 2011
30,000,000
April 20, 2011
3 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Akpeli Nordor

Employee

Amit Patel

Investor

Anne-Rachel Krostag

Employee

Charles R. Legg

Employee

Corey Bettencourt

Employee

Dawn Robinson

Employee

Jacob Ehrlich

Employee

Jason Yi

Employee

Jenny Severin

Employee

Marmi Le

Investor

Matthew Mackenzie

Employee

Megan Devine

Employee

Vanessa Belknap

Employee

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Ben Adams
March 17, 2021
FierceBiotech
Bluebird bio's chief medical officer David Davidson, M.D., is hitting the exit, though remaining as a consultant, as the biotech looks to navigate through its gene therapy issues.
Wolf Haldenstein Adler Freeman & Herz LLP
February 19, 2021
www.prnewswire.com:443
/PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a announces that a federal securities class action lawsuit has been filed in the...
Research and Markets
December 17, 2020
www.prnewswire.com:443
/PRNewswire/ -- The "Gene Therapy Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. Gene...

References

Page 1 of 2
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.